A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced skin cancers. However, potentially severe and irreversible immune-related adverse events (irAEs) represent a major clinical challenge. Identifying reliable predictive biomarkers for irAEs remains critical to balancing efficacy and toxicity.

Methods

In this prospective cohort of 131 skin cancer patients receiving ICI we analyzed the expression of 57 cytokines in baseline and longitudinal serum samples and tested their predictive value regarding the occurrence of irAEs.

Results

We observed distinct cytokine expression profiles in patients who developed irAEs compared to those who did not, with variations reflecting the affected organ systems, particularly liver and thyroid toxici

SUBMITTER: Flatt N 

PROVIDER: S-EPMC12696155 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature